Home Galena Biopharma Enrolls 700th Patient in NeuVax(TM) (nelipepimut-S) Phase 3 PRESENT Clinical Trial
 

Keywords :   


Galena Biopharma Enrolls 700th Patient in NeuVax(TM) (nelipepimut-S) Phase 3 PRESENT Clinical Trial

2015-02-09 18:35:24| Biotech - Topix.net

Galena Biopharma, Inc. , a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major medical needs across the full spectrum of cancer care, today announced enrollment of the 700th patient in the NeuVax Phase 3 PRESENT clinical trial. NeuVax is a first-in-class, HER2-directed cancer immunotherapy under evaluation to prevent breast cancer recurrence after standard of care treatment in the adjuvant setting.

Tags: present trial phase patient

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
05.11PM responds to Sir Alan Bates after repeated requests
05.11American Angus elects 2024-25 board leaders
05.11Atlantic Tropical Weather Outlook
05.11Eastern North Pacific Tropical Weather Outlook
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Public Advisory Number 8A
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Brazil gives green light to medicinal use of Cannabis in animals
More »